Biotechnology
Biopharmaceutical
Pharmaceutical

AMAG Pharmaceuticals

$10.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (1.99%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AMAG and other stocks, options, ETFs, and crypto commission-free!

About

AMAG Pharmaceuticals, Inc. Common Stock, also called AMAG Pharmaceuticals, is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Read More The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Employees
467
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
345.57M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
687.56K
High Today
$10.27
Low Today
$9.96
Open Price
$10.14
Volume
395.78K
52 Week High
$26.10
52 Week Low
$9.82

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Manufacturing
Health
Technology
Therapy
US

News

Yahoo FinanceMay 20

Is AMAG Pharmaceuticals, Inc.'s Balance Sheet A Threat To Its Future?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a small-cap stock with a market capitalization of US$349m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. Why is it important? Since AMAG is loss-making right now, it’s essential to understand the current state of its operations and pathway to profitability. Let's work through some financial hea...

2
Yahoo FinanceMay 20

New Strong Sell Stocks for May 20th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: AMAG Pharmaceuticals, Inc. AMAG is the owner and operator of a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 59.6% downward over the last 30 days. Annaly Capital Management, Inc. NLY is an investor and financer of residential and commercial assets. The Zacks Consensus Estimate for its current year earnings has been revised 9.4% downward over the last 30 days. Scroll to continue ...

2
Yahoo FinanceMay 9

Is AMAG Pharmaceuticals, Inc. A Good Stock To Buy?

How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after...

101

Earnings

-$1.59
-$0.78
$0.04
$0.85
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.